Posted inBiotechnology
Takeda, Alkermes lift lid on data for rival narcolepsy hopefuls as race to market heats up
Takeda and Alkermes both took data from their orexin receptor 2 (OX2R)-selective agonists to Singapore this morning as the race…
Posted inBiotechnology
Junshi heralds phase 3 psoriasis win for IL-17 drug, prepares push to Chinese regulators
Junshi Biosciences has announced that its IL-17 antibody hit the goals of a phase 3 psoriasis trial in China, setting…
Posted inGenetics
Fentanyl-Hunter: Machine Learning–Driven Screening for Opioid Metabolites
Fentanyl, a widely used synthetic opioid, can be fatal even at low exposures, and in recent years, the illegal abuse…
Posted inBiotechnology
BioNTech, BMS tout first global data for PD-L1xVEGF bispecific in small cell lung cancer, set phase 3 dose
BioNTech and its new partner Bristol Myers Squibb have trotted out the first global data for their PD-L1xVEGF bispecific in…
Posted inBiotechnology
Servier supercharges neuro pipeline with $450M deal for Fragile X syndrome candidate
Servier is souping up its neurology pipeline with a clinical-stage candidate sourced from U.K. biotech Kaerus Bioscience for a rare…
Posted inMedical Technology
Senseonics to retake Eversense CGM commercial control from Ascensia Diabetes Care
Senseonics plans to take back full commercial control of its Eversense continuous glucose monitoring platforms from its distribution partner Ascensia…
Posted inBiotechnology
Daiichi-Merck’s advanced lung cancer ADC sees 48% response rate in registrational trial
Partners Daiichi Sankyo and Merck & Co. are sharing new phase 2 data for their investigational antibody-drug conjugate, findings the…
Posted inMedical Technology
Medtronic’s Hugo robot logs success in hernia repair trial
While its Hugo surgical robot undergoes review at the FDA, Medtronic presented clinical data from its U.S. trial demonstrating success…
Posted inBiotechnology
‘Several concerning observations’: FDA sheds more light on reasons it rejected drugs
The FDA’s ongoing effort to establish a culture of “radical transparency” saw the agency publish another haul of complete response…
Posted inBiotechnology
Led by ex-HI-Bio CEO, Braveheart pays $65M to challenge BMS for heart disease market
Braveheart Bio has waded into the fight for a heart disease market, paying (PDF) $65 million upfront for a rival to…